Allergan and Ironwood Pharma settle Linzess patent dispute with Sandoz

Ironwood Pharmaceuticals (IRWD -2%) and licensee Allergan (AGN +0.1%) have settled their patent infringement litigation with Novartis’ (NVS -0.1%) Sandoz unit related to constipation med Linzess (linaclotide).

Under the terms of the settlement, Sandoz will have a non-exclusive license to market a generic version (145 mcg and 290 mcg) in the U.S. effective February 5, 2030 or earlier depending on certain circumstances.

https://seekingalpha.com/news/3529794-allergan-and-ironwood-pharma-settle-linzess-patent-dispute-sandoz